{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:48:07Z","timestamp":1793119687895,"version":"4.5.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>An 82-year-old woman with pulmonary aspergillosis developed dark-colored urine, markedly elevated creatine kinase (3,125\u202fU\/L) and myoglobin (3884.4\u202fng\/mL), and delayed myocardial injury (high-sensitivity troponin I: 26301.6\u202fpg\/mL) on day 2 after intravenous micafungin (200\u202fmg\/day) initiation. Symptoms and biomarkers resolved upon discontinuation, suggesting micafungin-induced rhabdomyolysis and myocardial injury. This first-reported case highlights the need for vigilance in elderly, multimorbid patients receiving polypharmacy, expanding understanding of micafungin\u2019s safety profile.<\/jats:p>","DOI":"10.3389\/fmed.2025.1708395","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T05:16:15Z","timestamp":1764825375000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Micafungin-induced rhabdomyolysis and myocardial injury: a case report"],"prefix":"10.3389","volume":"12","author":[{"given":"Qing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2400803","DOI":"10.1183\/13993003.00803-2024","article-title":"Fungal lung disease","volume":"64","author":"Jaggi","year":"2024","journal-title":"Eur Respir J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1080\/14756366.2022.2050224","article-title":"Echinocandins\u2014structure, mechanism of action and use in antifungal therapy","volume":"37","author":"Szyma\u0144ski","year":"2022","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.medcli.2021.09.025","article-title":"Rhabdomyolysis: a syndrome to be considered","volume":"158","author":"Baeza-Trinidad","year":"2022","journal-title":"Med Clin (Barc)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"101015","DOI":"10.1016\/j.disamonth.2020.101015","article-title":"Rhabdomyolysis","volume":"66","author":"Cabral","year":"2020","journal-title":"Dis Mon"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/cc2978","article-title":"Bench-to-bedside review: rhabdomyolysis\u2014an overview for clinicians","volume":"9","author":"Huerta-Alard\u00edn","year":"2005","journal-title":"Crit Care"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3390\/metabo10030106","article-title":"Antifungal drugs","volume":"10","author":"Hou\u0161\u0165","year":"2020","journal-title":"Meta"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/jof5030055","article-title":"Invasive aspergillosis by aspergillus flavus: epidemiology, diagnosis, antifungal resistance, and management","volume":"5","author":"Rudramurthy","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.diagmicrobio.2011.08.006","article-title":"In vitro activity of isavuconazole against 208 aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the european committee on antimicrobial susceptibility testing","volume":"71","author":"Rudramurthy","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3390\/antibiotics12050884","article-title":"Antifungals: from pharmacokinetics to clinical practice","volume":"12","author":"Carmo","year":"2023","journal-title":"Antibiotics"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1086\/589305","article-title":"Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against aspergillus and non-aspergillus hyphae","volume":"198","author":"Lamaris","year":"2008","journal-title":"J Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e00399-19","DOI":"10.1128\/AAC.00399-19","article-title":"Echinocandins for the treatment of invasive aspergillosis: from laboratory to bedside","volume":"63","author":"Aruanno","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40262-017-0578-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of micafungin","volume":"57","author":"Wasmann","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s12325-018-0762-5","article-title":"Effectiveness and tolerability of micafungin in Chinese patients with invasive fungal infections: a retrospective, multicenter study","volume":"35","author":"Zheng","year":"2018","journal-title":"Adv Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/jcpt.12386","article-title":"Micafungin and a case of polymorphic ventricular tachycardia","volume":"41","author":"Shah","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00415-019-09185-4","article-title":"A systematic review on the definition of rhabdomyolysis","volume":"267","author":"Stahl","year":"2020","journal-title":"J Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.3390\/v14102255","article-title":"Rhabdomyolysis after COVID-19 infection: a case report and review of the literature","volume":"14","author":"Bawor","year":"2022","journal-title":"Viruses"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.2169\/internalmedicine.54.4136","article-title":"Rhabdomyolysis caused by Candida parapsilosis in a patient with acute myeloid leukemia after bone marrow transplantation","volume":"54","author":"Kakiuchi","year":"2015","journal-title":"Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e59975","DOI":"10.7759\/cureus.59975","article-title":"Causality, severity, preventability and predictability assessments scales for adverse drug reactions: a review","volume":"16","author":"Manjhi","year":"2024","journal-title":"Cureus"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1515\/cclm-2023-0313","article-title":"Safety monitoring of drug-induced muscle injury and rhabdomyolysis: a biomarker-guided approach for clinical practice and drug trials","volume":"61","author":"Ostrowski","year":"2023","journal-title":"Clin Chem Lab Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13054-016-1314-5","article-title":"Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice","volume":"20","author":"Chavez","year":"2016","journal-title":"Crit Care"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.3390\/biomedicines11051485","article-title":"Developing in vitro models to define the role of direct mitochondrial toxicity in frequently reported drug-induced rhabdomyolysis","volume":"11","author":"Bin Dayel","year":"2023","journal-title":"Biomedicine"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.mito.2023.05.004","article-title":"The cyclic lipopeptide micafungin induces rupture of isolated mitochondria by reprograming the mitochondrial inner membrane anion channel","volume":"71","author":"Hosler","year":"2023","journal-title":"Mitochondrion"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"697330","DOI":"10.3389\/fphar.2021.697330","article-title":"Adverse effects associated with currently commonly used antifungal agents: a network meta-analysis and systematic review","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.14503\/THIJ-15-5690","article-title":"Does myocardial necrosis occur in rhabdomyolysis?","volume":"43","author":"Aisenberg","year":"2016","journal-title":"Tex Heart Inst J"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/s0750-7658(00)00113-1","article-title":"Myocardial rhabdomyolysis following paraphenylene diamine poisoning","volume":"19","author":"Ababou","year":"2000","journal-title":"Ann Fr Anesth Reanim"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/tropicalmed7020023","article-title":"Characterizing safety and clinical outcomes associated with high-dose micafungin utilization in patients with proven invasive candidiasis","volume":"7","author":"Grant","year":"2022","journal-title":"Trop Med Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/sj.bmt.1705398","article-title":"A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation","volume":"38","author":"Sirohi","year":"2006","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1708395\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T05:16:16Z","timestamp":1764825376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1708395\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":27,"alternative-id":["10.3389\/fmed.2025.1708395"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1708395","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"article-number":"1708395"}}